Publication Date

2015

Document Type

Thesis

Committee Members

Timothy Cope (Advisor), Larry Ream (Committee Member), Mark Rich (Committee Member)

Degree Name

Master of Science (MS)

Abstract

There is currently no direct evidence that chemotherapy induced peripheral neuropathy (CIPN) necessarily explains the sensorimotor deficits seen in 90% patients treated with oxaliplatin (OX). Some patients develop sensory symptoms without CIPN. Our laboratory reported abnormal signaling from IA afferents in OX treated rats with no evidence of neuropathy. We hypothesized that in the absence of CIPN, the behavioral disability is associated with impaired sensory encoding in OX treated rats. The purpose of this study was to investigate the sensorimotor abilities of OX treated rats. The battery of behavioral tests was designed to address proprioception and sensorimotor integration. In the absence of CIPN, few OX rats revealed signs of decreased performance, as compared to controls. In conclusion, this study reproduced some of the results seen in the clinical studies and established a rat model, which can be used in further investigation of chronic sensorimotor symptoms of OX.

Page Count

56

Department or Program

Department of Neuroscience, Cell Biology & Physiology

Year Degree Awarded

2015


Share

COinS